Health Technology Assessment

All Items

• Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage IV Hodgkin lymphoma in Italy

  Chiara Bini, Andrea Marcellusi, Francesco Saverio Mennini, Silvia Ripoli, Laura Fioravanti, Victoria Federico Paly, Alexa Molinari, Paolo Morelli, Stanimira Krotneva, Shujun Li

  248-257

  DOI: https://doi.org/10.33393/grhta.2024.3167

• A 1-year per-patient cost of therapy administration analysis of mosunetuzumab and tisagenlecleucel in relapsed or refractory follicular lymphoma patients receiving two or more lines of systemic therapy

  Marco Bellone, Alice Sabinot, Alessandro D’Arpino, Emanuela Omodeo Salè, Daniela Ghislieri, Lorenzo Pradelli

  239-247

  DOI: https://doi.org/10.33393/grhta.2024.3170

• Economic impact of dapagliflozin in the management of chronic kidney disease in Italy: results from a micro-simulation model

  Roberto Ravasio, Andrea Marcellusi, Luca De Nicola

  231-238

  DOI: https://doi.org/10.33393/grhta.2024.3309

• A cost-effectiveness analysis of Navina Smart on adult patients affected by neurogenic bowel dysfunction

  Matteo Ruggeri, Alessandro Signorini, Silvia Caravaggio, Gabriele Righi

  214-222

  DOI: https://doi.org/10.33393/grhta.2024.3168

• The economic and social burden of congenital thrombotic thrombocytopenic purpura (cTTP) in Italy

  Filippo Rumi, Michele Basile, Eugenio Di Brino, Agostino Fortunato, Debora Antonini

  200-206

  DOI: https://doi.org/10.33393/grhta.2024.3147

• Budget impact analysis on the Italian healthcare system of roxadustat for the treatment of anemia due to chronic kidney disease

  Chiara Bini, Andrea Marcellusi, Paolo Di Rienzo, Lucia Del Vecchio

  175-190

  DOI: https://doi.org/10.33393/grhta.2024.3062

• The efficacy of dalbavancin and impact on hospitalization and treatment costs in patients with ABSSSI

  Sergio Carbonara

  13-17

  DOI: https://doi.org/10.33393/grhta.2024.3045

• Clinical pharmacy and telemedicine: an opportunity to improve epilepsy management

  Rossella Moscogiuri

  11-10

  DOI: https://doi.org/10.33393/grhta.2024.3095

• Gender differences and hypercholesterolemia: real-world evidence from the study WECARE (Women Effective CArdiovascular Risk Evaluation)

  Valentina Perrone, Gerardo Medea, Stefano Urbinati, Diego Sangiorgi, Luca Degli Esposti

  138-147

  DOI: https://doi.org/10.33393/grhta.2024.2731

• Determining value in the treatment of activated PI3Kδ syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholders

  Alicia Gil, María Reyes Abad, Carmen Alerany, Laia Alsina, Eduardo López Granados, Olaf Neth, José Luis Poveda, Jacques G. Rivière, Carlos Rodríguez-Gallego, Joanne B. Tutein Nolthenius, Raquel Figueiredo , Silvia Subías Labazuy

  124-130

  DOI: https://doi.org/10.33393/grhta.2024.3041

• Patient-reported outcomes in epilepsy: a case study exploring their usage and impact

  Simona Lattanzi, Angela La Neve

  108-114

  DOI: https://doi.org/10.33393/grhta.2024.3020

• Costs and benefits in patients with NYHA class III heart failure treated with CardioMEMS in Italy

  Andrea Messori, Maria Rita Romeo, Valeria Fadda, Francesca Collini, Sabrina Trippoli

  105-107

  DOI: https://doi.org/10.33393/grhta.2024.3018

• Heart failure and economic impact: an analysis in real clinical practice in Italy

  Melania Dovizio, Melania Leogrande, Luca Degli Esposti

  94-100

  DOI: https://doi.org/10.33393/grhta.2024.3013

• The socioeconomic burden of adult attention-deficit/hyperactivity disorder in Spain

  Maria Merino, Paulina Maravilla-Herrera, Teresa Martín Lorenzo, Juan Antonio Arance, Julio Bobes, Montse Corrales, Fátima Guzmán, María Morales, Carlos Mur

  82-93

  DOI: https://doi.org/10.33393/grhta.2024.2697

• The role and impact of health economics in the optimization of patient care in osteoarthritis: insights from a practical example

  Mickaël Hiligsmann, Olivier Bruyère

  75-81

  DOI: https://doi.org/10.33393/grhta.2024.2682

• Cost per Number Needed to Treat (NNT) for upadacitinib in the treatment of bio-exposed patients with moderately-severely active ulcerative rectocolitis

  Flavio Caprioli, Massimo Claudio Fantini, Francesca Marando, Dario Scaduto, Roberto Ravasio

  55-67

  DOI: https://doi.org/10.33393/grhta.2024.2658

• Cost per NNT for upadacitinib in the treatment of patients with moderate-severe atopic dermatitis in Italy

  Andrea Chiricozzi, Antonio Costanzo, Anna Levi, Federica Parretta, Roberto Ravasio

  38-50

  DOI: https://doi.org/10.33393/grhta.2024.2728

• Clinical and economic burden of peristomal skin complications: Activity Based Costing analysis

  Agostino Fortunato, Filippo Rumi, Massimo Zazzetta, Marco Della Valle, Vincenzo Pedace, Americo Cicchetti

  31-37

  DOI: https://doi.org/10.33393/grhta.2024.2639

• A pharmacoeconomic analysis from Italian guidelines for the management of prolactinomas

  Michele Basile, Ilaria Valentini, Roberto Attanasio, Renato Cozzi, Agnese Persichetti, Irene Samperi, Alessandro Scoppola, Renata Simona Auriemma, Ernesto De Menis, Felice Esposito, Emanuele Ferrante, Giuseppe Iatì, Diego Mazzatenta, Maurizio Poggi, Roberta Rudà, Fabio Tortora, Fabio Cruciani, Zuzana Mitrova, Rosella Saulle, Simona Vecchi, Paolo Cappabianca, Agostino Paoletta, Alessandro Bozzao, Marco Caputo, Francesco Doglietto, Francesco Ferraù, Andrea Gerardo Lania, Stefano Laureti, Stefano Lello, Davide Locatelli, Pietro Maffei, Giuseppe Minniti, Alessandro Peri, Chiara Ruini, Fabio Settanni, Antonio Silvani, Nadia Veronese, Franco Grimaldi, Enrico Papini, Americo Cicchetti

  1-16

  DOI: https://doi.org/10.33393/grhta.2024.2601

• Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2−, node-positive, high-risk early breast cancer in Italy

  Alison Davie, Sory Traoré, Massimo Giovannitti, Giuseppe Pompilio, Mark Lambton, Esra Cakar, Anuja Chatterjee

  62-69

  DOI: https://doi.org/10.33393/grhta.2023.2561

• Good practices for the development of budget impact models at regional level

  Andrea Marcellusi, Angela Ragonese, Andrea Marinozzi, Alberto Bortolami, Sara Mucherino, Carolina Moreno, Amalia Antenori, Matteo Ferrario, Claudia Simonelli, Matteo Zanuzzi, Marco Cicoira, Ruggero Lasala, Francesco Russoniello, Francesco Attanasio, Caterina Donati, Chiara Roni, Fabrizio Gemmi, Francesco Saverio Mennini, Pierluigi Russo, Giovanna Scroccaro, PierLuigi Canonico

  53-61

  DOI: https://doi.org/10.33393/grhta.2023.2582

• COVID-19 impact on the decision process of the Italian Medicine Agency: a quantitative assessment

  Beatrice Canali, Laura Candelora, Francesca Fiorentino, Tom Halmos, Paola La Malfa, Francesca Massara, Chiara Vassallo, Duccio Urbinati

  46-52

  DOI: https://doi.org/10.33393/grhta.2023.2560

• Cost-effectiveness of IMI/CIL/REL for the treatment of carbapenem non-susceptible Gram-negative bacterial infections

  Martina Paoletti, Andrea Marcellusi, Joe Yang, Francesco Saverio Mennini

  18-28

  DOI: https://doi.org/10.33393/grhta.2023.2488

• Budget impact analysis of enzalutamide for the treatment of hormone-sensitive metastatic prostate cancer in Italy

  Francesca Fiorentino, Paolo Di Rienzo

  29-39

  DOI: https://doi.org/10.33393/grhta.2023.2507

• Budget Impact analysis of a new system of care in Parkinson’s disease patients

  Chiara Bini, Francesco Saverio Mennini, Andrea Marcellusi, Martina Paoletti, Carlo Tomino

  91-98

  DOI: https://doi.org/10.33393/grhta.2022.2413